Senaste nyheterna
18 April 2023
Gedea Biotech obtains US-patent covering pHyph for antibiotic-free treatment and prevention of bacterial vaginosis
Lund, Sweden, April 18, 2023. Swedish women’s health company Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO)…
12 April 2023
Gedea Biotech appoints Anna-Karin Areskog as QA Director and receives ISO13485 certification
Lund, Sweden April 12, 2023: Gedea Biotech announces today that Anna-Karin Areskog has been appointed QA Director and that their ISO13485*…
4 April 2023
Gedea Biotech awarded SEK 3M from SWElife and MedTech4Health for groundbreaking antibiotic free women’s health trial
Lund, Sweden, April 4, 2023: Gedea Biotech today announced it has been awarded SEK 3M grant from the Swedish innovation programs, SWElife and…
5 December 2022
Two mentions and one article in three publications during end of November
The results from the NEFERTITI-study have received much attention since they were first published in a press release from October 11th. During the…
14 November 2022
Gedea Biotech reports results from placebo-controlled clinical trial of pHyph, an antibiotic-free treatment for bacterial vaginosis
Symptom reduction was seen in 90% of patients and absence of symptoms was noted in 70% of patients. Clinical cure rate was 50,4% in the pHyph group,…
18 May 2022
Gedea Biotech to Start EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
Gedea Biotech today announces that it has received regulatory approval from the Ethics Committee and the Swedish Medical Products Agency and will…
Press kit
Klicka för att ladda ner logotyper och bilder
